Pharmaceutical Technology29d agobullish
MSD wins FDA approval for cholesterol pill to help plug Keytruda voidMSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
52last 24h
1809last 7d
299● bullish (7d)
171● bearish (7d)
205publishers
Yahoo Personal Finance30d agoneutral
FDA approves first-of-its-kind cholesterol pill Lipfendra: What it will costThe daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.
The Wall Street Journal30d agoneutral
Merck’s First-of-Its-Kind Cholesterol Pill Approved, Ushering in New Wave of TreatmentLipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.
Reuters46d agobearish
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trialsJune 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
Insider Monkey48d agobullish
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBCGilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]